Evidence map›Paper›PMID 19110031›Full record

ArticleNeuroscience letters2009

Cell-specific loss of kappa-opioid receptors in oligodendrocytes of the dysmyelinating jimpy mouse.

Pamela E Knapp, Valeriya V Adjan, Kurt F Hauser

Open access · greenAbstract read
In one paragraph

Article in Neuroscience letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Opioid and neuroHIV Comorbidity - Current and Future Perspectives.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  2. Article
  3. Review
  4. Enhancing Remyelination through a Novel Opioid-Receptor Pathway.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Pamela E KnappDepartment of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond, VA 23298, USA. peknapp@vcu.edu <peknapp@vcu.edu>
Valeriya V Adjan
Kurt F Hauser
Virginia Commonwealth University · USUniversity of Kentucky · US

Funding

Opiate drug abuse and CNS vulnerability to HIVP01DA019398 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2005 to 2009
$5.0M
Opioids Modulate Oligodendrocyte Development &FunctionR01DA015097 · NIDA · UNIVERSITY OF KENTUCKY · PI KNAPP, PAMELA E · 2003 to 2006
$1.0M
NIDA NIH HHS P01 DA019398NIDA NIH HHS P01 DA19398NIDA NIH HHS R01 DA015097NIDA NIH HHS R01 DA15097
6 · The paper itself

Abstract

Jimpy is a murine mutation in myelin proteolipid protein, leading to premature death of oligodendrocytes and severe central nervous system hypomyelination. Jimpy is a bona fide model of human Pelizaeus-Merzbacher disease. This paper describes a severe reduction in expression of kappa-opioid receptors (KOP) in oligodendrocytes of jimpy mice. A cell-specific reduction of >90% is apparent by 5 days of age. Expression is not reduced in neurons, and mu-opioid receptor expression is normal. Mechanism(s) leading to deficient KOP expression in jimpy mice remain unclear. We speculate that loss of KOP may be related to increased [Ca(2+)](i) and premature death of jimpy oligodendrocytes.

Indexed as

AnimalsCalcium SignalingCell DeathDisease Models, AnimalDown-RegulationHereditary Central Nervous System Demyelinating DiseasesMiceMice, JimpyNerve Fibers, MyelinatedOligodendrogliaPelizaeus-Merzbacher DiseaseReceptors, Opioid, kappaReceptors, Opioid, kappa

Identifiers

PMID19110031
PMCPMC4029417
OpenAlexW1972142916

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.